<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761215</url>
  </required_header>
  <id_info>
    <org_study_id>1986-007</org_study_id>
    <secondary_id>TR701-104</secondary_id>
    <nct_id>NCT00761215</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections</brief_title>
  <official_title>A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III
      studies in patients with complicated skin and skin structure infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2008</start_date>
  <completion_date type="Actual">February 24, 2009</completion_date>
  <primary_completion_date type="Actual">February 24, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set</measure>
    <time_frame>7 to 14 days after the last dose of study drug</time_frame>
    <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set</measure>
    <time_frame>7-14 days after last dose of study drug</time_frame>
    <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate at End of Therapy</measure>
    <time_frame>last day of study treatment</time_frame>
    <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set</measure>
    <time_frame>7-14 days after last dose of study drug</time_frame>
    <description>Satisfactory microbiological outcomes are eradication and presumed eradication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set</measure>
    <time_frame>21 to 28 days after the last study drug</time_frame>
    <description>Persistent clinical cure was defined as continuing favorable response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Safety Profile of Tedizolid Phosphate</measure>
    <time_frame>Multiple</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK</measure>
    <time_frame>Multiple</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set</measure>
    <time_frame>21-28 days after last study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Skin Diseases, Infectious</condition>
  <condition>Skin Diseases, Bacterial</condition>
  <arm_group>
    <arm_group_label>TR-701 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TR-701 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TR-701 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 200 mg</intervention_name>
    <description>oral TR-701 200 mg for 5 to 7 days</description>
    <arm_group_label>TR-701 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 300 mg</intervention_name>
    <description>oral TR-701 300 mg for 5 to 7 days</description>
    <arm_group_label>TR-701 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 400 mg</intervention_name>
    <description>TR-701 400 mg for 5 to 7 days</description>
    <arm_group_label>TR-701 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with complicated skin and skin structure infection with at least 2 signs and
             symptoms

          -  Suspected or confirmed infection due to a gram-positive organism

        Exclusion Criteria:

          -  Complicated skin and skin structure infection due to gram-negative organisms

          -  Complicated skin and skin structure infections requiring more than 7 days of therapy

          -  Uncontrolled diabetes

          -  Chronic systemic immunosuppressive therapy

          -  AIDS with CD4 count &lt; 200 cells/mm3

          -  Uncontrolled hypertension

          -  Mild moderate or severe renal failure

          -  Severe hepatic disease

          -  Neutropenia

          -  Use of antidepressants such as SSRIs or MAOIs for 14 days before first dose of study
             drug

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Study Site #011</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #001</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study Site #009</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #002</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #010</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site 007</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site 003</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site 004</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #006</name>
      <address>
        <city>Ludowici</city>
        <state>Georgia</state>
        <zip>31316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #005</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Study site #012</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius study sie #008</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <results_first_submitted>July 15, 2014</results_first_submitted>
  <results_first_submitted_qc>July 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <disposition_first_submitted>April 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 30, 2014</disposition_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin</keyword>
  <keyword>Infection</keyword>
  <keyword>Complicated Skin and Skin Structure Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TR-701 200 mg</title>
          <description>Oral TR-701 200 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="P2">
          <title>TR-701 300 mg</title>
          <description>Oral TR-701 300 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="P3">
          <title>TR-701 400 mg</title>
          <description>Oral TR-701 400 mg once daily for 5 to 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but didn't receive drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bacteremia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>TR-701 200 mg</title>
          <description>Oral TR-701 200 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="B2">
          <title>TR-701 300 mg</title>
          <description>Oral TR-701 300 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="B3">
          <title>TR-701 400 mg</title>
          <description>Oral TR-701 400 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="12.1"/>
                    <measurement group_id="B2" value="36.0" spread="12.4"/>
                    <measurement group_id="B3" value="35.8" spread="12.0"/>
                    <measurement group_id="B4" value="36.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set</title>
        <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
        <time_frame>7 to 14 days after the last dose of study drug</time_frame>
        <population>The Clinically Evaluable analysis set includes data from all participants who had a diagnosis of cSSSI, received minimal study therapy, completed an assessment, and had no confounding events or factors.</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set</title>
          <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
          <population>The Clinically Evaluable analysis set includes data from all participants who had a diagnosis of cSSSI, received minimal study therapy, completed an assessment, and had no confounding events or factors.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.4" upper_limit="100"/>
                    <measurement group_id="O2" value="94.4" lower_limit="84.6" upper_limit="98.8"/>
                    <measurement group_id="O3" value="94.4" lower_limit="84.6" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set</title>
        <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
        <time_frame>7-14 days after last dose of study drug</time_frame>
        <population>The clinically modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection.</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate at Test of Cure in the Clinical Modified Intent to Treat Analysis Set</title>
          <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
          <population>The clinically modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="78.4" upper_limit="95.4"/>
                    <measurement group_id="O2" value="88.9" lower_limit="78.4" upper_limit="95.4"/>
                    <measurement group_id="O3" value="85.5" lower_limit="74.2" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate at End of Therapy</title>
        <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
        <time_frame>last day of study treatment</time_frame>
        <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate at End of Therapy</title>
          <description>Clinical response was defined as resolution or improvement of signs and symptoms of the complicated skin and skin structure infection so that no further antibiotic therapy was required.</description>
          <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="84.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="90.5" lower_limit="80.4" upper_limit="96.4"/>
                    <measurement group_id="O3" value="91.9" lower_limit="82.2" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set</title>
        <description>Satisfactory microbiological outcomes are eradication and presumed eradication</description>
        <time_frame>7-14 days after last dose of study drug</time_frame>
        <population>The microbiologically evaluable analysis set includes all participants who received study drug, had a diagnosis of complicated skin and skin structure infection, completed an assessment, had no confounding events or factors, and had a baseline Gram-positive bacterial pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Response Rate at Test of Cure in the Microbiologically Evaluable Analysis Set</title>
          <description>Satisfactory microbiological outcomes are eradication and presumed eradication</description>
          <population>The microbiologically evaluable analysis set includes all participants who received study drug, had a diagnosis of complicated skin and skin structure infection, completed an assessment, had no confounding events or factors, and had a baseline Gram-positive bacterial pathogen.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="93.2" lower_limit="81.3" upper_limit="98.6"/>
                    <measurement group_id="O3" value="100" lower_limit="92.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set</title>
        <description>Persistent clinical cure was defined as continuing favorable response.</description>
        <time_frame>21 to 28 days after the last study drug</time_frame>
        <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection. Microbiological samples not available from all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome at the Late Follow-up Visit in the Clinical Modified Intent to Treat Analysis Set</title>
          <description>Persistent clinical cure was defined as continuing favorable response.</description>
          <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection. Microbiological samples not available from all participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                    <measurement group_id="O2" value="98.2"/>
                    <measurement group_id="O3" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Safety Profile of Tedizolid Phosphate</title>
        <time_frame>Multiple</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK</title>
        <time_frame>Multiple</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set</title>
        <time_frame>21-28 days after last study drug</time_frame>
        <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection. Microbiological samples not available from all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>TR-701 200 mg</title>
            <description>Oral TR-701 200 mg once daily for 5 to 7 days</description>
          </group>
          <group group_id="O2">
            <title>TR-701 300 mg</title>
            <description>Oral TR-701 300 mg once daily for 5 to 7 days</description>
          </group>
          <group group_id="O3">
            <title>TR-701 400 mg</title>
            <description>Oral TR-701 400 mg once daily for 5 to 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Recurrence at Late Follow-up in Clinical Modified Intent to Treat Analysis Set</title>
          <population>The clinical modified intent to treat analysis set includes data from all participants who received study drug and had a diagnosis of complicated skin and skin structure infection. Microbiological samples not available from all participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6.4"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were to be collected after informed consent through last visit (up to 36 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TR-701 200 mg</title>
          <description>Oral TR-701 200 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="E2">
          <title>TR-701 300 mg</title>
          <description>Oral TR-701 300 mg once daily for 5 to 7 days</description>
        </group>
        <group group_id="E3">
          <title>TR-701 400 mg</title>
          <description>Oral TR-701 400 mg once daily for 5 to 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical trial agreement between Sponsor and Investigators. Sponsor approval is required for publication of any data subsets. Final authorship will be determined by contributions to study design, enrollment, data analysis, and/or interpretation of the results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philippe Prokocimer, MD</name_or_title>
      <organization>Cubist Pharmaceuticals, Inc.</organization>
      <phone>858-452-0370 ext 241</phone>
      <email>philippe.prokocimer@cubist.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

